September 13, 2016 8:30am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane
Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly
owned subsidiary, BioReference Laboratories, effective October 1, 2016.
Ms. Wood is a nationally respected healthcare attorney who has been
practicing law for 29 years. She specializes in laboratory regulatory
and compliance matters, and has counseled more than 500 pathology groups
and 350 clinical laboratories. For the past 28 years she has been with
the multi-state law firm McDonald Hopkins LLC, where she is a member of
the firm’s board of directors. Ms. Wood is a frequent speaker at
national and state laboratory and pathology meetings, is a contributor
to association publications and is regularly quoted in the national
press. Ms. Wood graduated from the Vanderbilt University School of Law.
"We are delighted to welcome Jane to the BioReference Laboratories team.
She has a distinguished legal career, having counseled a multitude of
pathology practices and clinical laboratories across the country; she is
considered one of the leading legal experts in the field. Her diverse
experience and insight on matters impacting the diagnostics and
laboratory industries will be of great value as we continue to deliver
high quality diagnostic services to improve patient care," said Gregory
S. Henderson, M.D., Ph.D., President of BioReference Laboratories.
About BioReference Laboratories, Inc.
BioReference Laboratories is one of the largest and fastest growing
full-service diagnostic laboratories in the world, providing clinical
testing services to physician offices, clinics, hospitals, long-term
care facilities and employers while also advancing drug discovery and
development with disease foundations, academic and pharmaceutical
partners. BioReference's comprehensive testing capabilities and
expertise spans molecular diagnostics, anatomical pathology, women's
health, oncology and rare disease genetics. For more information, visit www.bioreference.com .
About OPKO Health
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes BioReference Laboratories, the
third-largest clinical laboratory in the U.S. with a core genetic
testing business and a 420-person sales force to drive growth and sell
new products, such as the 4Kscore® prostate cancer test and the Claros®
1 in office immunoassay platform. Our pharmaceutical business features
RAYALDEE®, an FDA-approved treatment for stage 3-4 CKD patients with
secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™
for chemotherapy-induced nausea and vomiting (oral formulation launched
by partner Tesaro and IV formulation PDUFA is January 2017). Our
biologics products under development are hGH-CTP, a once-weekly human
growth hormone for injection (partnered with Pfizer), long-acting Factor
VIIa for hemophilia (in Phase 2a) and a long-acting oxyntomodulin for
diabetes and obesity (in Phase 1). OPKO has production and distribution
assets in several countries abroad, strategic investments and an active
business development strategy. More information is available at www.opko.com .
Forward-looking Statements
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding our ability to generate or
accelerate growth at BioReference, our ability to transition and
transform the diagnostics and laboratory industry or improve patient
care through BioReference, our ability to commercialize important new
products, and BioReference's or OPKO's ability to deliver high-value or
innovative new testing to clinicians and patients, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products, financial
condition, strategies or prospects. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors include
those described in our filings with the Securities and Exchange
Commission, as well as the risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments. In addition, forward-looking
statements may also be adversely affected by general market factors,
competitive product development, product availability, federal and state
regulations and legislation, challenges relating to integration of
BioReference, including management changes, the regulatory process for
new products and indications, manufacturing issues that may arise,
patent positions and litigation, among other factors. The
forward-looking statements contained in this press release speak only as
of the date the statements were made, and we do not undertake any
obligation to update forward-looking statements. We intend that all
forward-looking statements be subject to the safe-harbor provisions of
the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160913005468/en/
OPKO Health, Inc.
Company
OPKO Health, Inc.
Tara
Mackay, 305-575-4100
Investor Relations
or
Media
Rooney
Partners
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released September 13, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page